Healthy volunteers test new rilzabrutinib tablet formulation
NCT ID NCT06342700
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested two different tablet forms of the drug rilzabrutinib in 28 healthy adults. The goal was to see how well each form is absorbed by the body, both with and without food. Participants took a single dose of each tablet in a random order, with a day off between doses. This trial does not aim to treat any disease, but to gather information for future drug development.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rilzabrutinib
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Site Number : 8400001
Saint Paul, Minnesota, 55114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults